A cluster of European cancer‑vaccine companies announced new financing and clinical progress: Accession, Infinitopes and Ervimmune secured fresh capital, with off‑the‑shelf and improved targeting platforms moving into first‑in‑human studies. Ervimmune specifically closed a €17 million Series A to advance its ErVac‑01 into clinical testing. The funding wave highlights investor interest in next‑generation therapeutic vaccines that promise off‑the‑shelf scalability compared with personalized mRNA approaches.